What is the brand name for Sofosbuvir Velpatasvir?

Sofosbuvir/velpatasvir, sold under the brand name Epclusa among others, is a fixed-dose combination medication for the treatment of hepatitis C in adults.

What is the use of Sofosbuvir Velpatasvir?

Sofosbuvir and velpatasvir is a combination antiviral medicine used to treat chronic hepatitis C in adults and children at least 6 years old or weighing at least 37 pounds (17 kilograms).

How do you take Sofosbuvir and Velpatasvir?

This medication works best when the amount of drug in your body is kept at a constant level. Take this drug at evenly spaced intervals. To help you remember, take it at the same time each day. Continue to take sofosbuvir/velpatasvir for the full length of time prescribed, even if symptoms disappear after a short time.

What company makes Epclusa?

Epclusa and Gilead are registered trademarks of Gilead Sciences, Inc. , or its related companies. For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Does Epclusa have generic?

What are the new generics? Harvoni’s new generic is ledipasvir/sofosbuvir and Epclusa’s new generic is velpatasvir/sofosbuvir. Both of these new generics are exact replicas of their brand-name counterparts, with the same forms and strengths.

Who makes Vosevi?

The manufacturer of Vosevi, Gilead Sciences, states that there have been cases of problems in some people who have taken the heart drug amiodarone and medicines containing sofosbuvir. Vosevi contains sofosbuvir.

What is the best Hep C treatment?

Hepatitis C is treated using direct acting antiviral (DAA) tablets. DAA tablets are the safest and most effective medicines for treating hepatitis C. They’re highly effective at clearing the infection in more than 90% of people. The tablets are taken for 8 to 12 weeks.

Is sofosbuvir Velpatasvir the same as Epclusa?

Epclusa (ep-KLOO-suh) is a fixed dose combination of sofosbuvir and velpatasvir (Figure 1). It is manufactured by Gilead Sciences.

Is sofosbuvir velpatasvir the same as Epclusa?

How long do you take sofosbuvir velpatasvir?

It is taken usually with or without food once a day for 12 weeks. Take sofosbuvir and velpatasvir at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand.

Which is better Epclusa or Harvoni?

Which is more effective: Epclusa or Harvoni? Although both Epclusa and Harvoni are effective for treating hepatitis C, Epclusa may cure a greater percentage of people than Harvoni does. Epclusa was approved in 2016 and was the first medication approved that was effective at treating all six hepatitis C genotypes.

Where is Epclusa manufactured?

Epclusa is manufactured and marketed by Gilead Sciences, Inc., of Foster City, California.

How does velpatasvir interact with the transporter proteins?

Interactions. Velpatasvir is both an inhibitor and a substrate of the transporter proteins P-glycoprotein (Pgp), ABCG2, OATP1B1 and OATP1B3. It is partly degraded by the liver enzymes CYP2B6, CYP2C8 and CYP3A4. Substances that are transported or inactivated by these proteins, or interfere with them, can interact with velpatasvir.

What’s the difference between sofosbuvir and velpatasvir?

Sofosbuvir is in a class of antiviral medications called nucleotide hepatitis C virus (HCV) NS5B polymerase inhibitors. Velpatasvir is in a class of antiviral medications called HCV NS5A replication complex inhibitors.

Are there any side effects to taking velpatasvir?

Side effects in studies occurred with similar frequencies as in people treated with placebo. Velpatasvir is both an inhibitor and a substrate of the transporter proteins P-glycoprotein (Pgp), ABCG2, OATP1B1 and OATP1B3. It is partly degraded by the liver enzymes CYP2B6, CYP2C8 and CYP3A4.

How is velpatasvir used to treat hepatitis C?

Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. It is a selective inhibitor of HCV RNA replication with mean 50% effective concentrations (EC50s) against GT1 to GT6 of 6 to 130 pM [2].